Brentuximab vedotin maintenance post-ASCT for high-risk cHL (AETHERA, 16 cycles)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-BRENTUXIMAB-VEDOTIN |
|---|
| ID | REG-BRENTUXIMAB-MAINTENANCE-CHL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-HODGKIN-2024 SRC-NCCN-BCELL-2025 |
Notes
AETHERA trial (Moskowitz 2015, follow-up 2018): post-ASCT cHL with high-risk features (primary refractory, relapse <12 mo from 1L, extranodal disease at relapse) randomized to BV maintenance × 16 cycles vs placebo — 5-y PFS 59% vs 41% (HR 0.52). FDA-approved for post-ASCT cHL high-risk maintenance. Particularly relevant for primary-refractory cHL where standard salvage + ASCT alone has high relapse rates. Pre-existing peripheral neuropathy is dominant patient-selection criterion — Grade ≥2 = practically non-eligible. Funding gap in UA — fundraising pathway often required.
Used By
Indication
IND-CHL-2L-BRENTUXIMAB-MAINTENANCE- IND-CHL-2L-BRENTUXIMAB-MAINTENANCE